News

BGPartner keeps its know-how in construction and planning law up to date. Our team, represented by Olivier Bula and Maja Rasovic, attended the Construction Law Conference in Freiburg.

The Construction Law Conference of the University of Freiburg is one of the most important and renowned Swiss events and a must for every construction lawyer. Every two years, numerous experts from the areas of law, economics, public administration and construction practice meet at the University of Freiburg to discuss the latest issues in private and public construction law.

Would you like to learn more about our law expertise? Please klick here.

SynAct Pharma AB, a Swedish listed biotechnology company (Nasdaq Stockholm: SYNACT), acquires 100% of TXP Pharma AG, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. BGPartner assisted SynAct Pharma AB in the negotiations and advised on all Swiss legal matters regarding this international M&A transaction.  

Through the acquisition of TXP Pharma AG, SynAct Pharma AB’s position as a leader within therapies for resolution treatment through melanocortin biology is strengthened. The acquisition gives SynAct Pharma AB two platforms that complement each other and create a versatility to develop therapies to address the full range of inflammatory and autoimmune diseases. The development portfolio is strengthened, and the aim is that SynAct Pharma AB will shortly have two projects in clinical development and another two in a relatively advanced preclinical phase.

The purchase price consisted of a fixed purchase price of approximately SEK 136 million (approximate CHF 12 million) and a conditional additional purchase price of SEK 55 million (approximate CHF 5 million). The fixed purchase price has been paid through newly issued shares in SynAct Pharma AB.

The team of BGPartner was led by Oliver Gnehm (Partner) and further consisted of Alain P. Röthlisberger (Partner) and Victoria Marty (Associate).

More information about our negotiation expertise can be found here. The press release of SynAct Pharma AB can be found here.

BGPartner is pleased to welcome Louis Moser (Substitut) to the Berne team as of January 1, 2023. Further information on Louis Moser and our entire team can be found here.

On behalf of our partners and the whole team, we are delighted to announce that our Of Counsel Alain P. Röthlisberger will become a partner, effective 1 January 2023.

Alain joined BGPartner in 2021, with a focus on corporate and commercial law, including M&A and regulatory. He is also heading BGPartner's Middle East Desk and in charge of our financial intermediary services. Alain has a proven record of more than 25 years of experience as Attorney-at-law, Corporate and General Counsel. Most recently, he had been Almarai Company's Group General Counsel. His experience covers legal advice and transactions in Switzerland, Europe, North Africa, Middle East, Asia (incl. China) and the US.

We would like to congratulate Alain to this step and wish him lots of success in our partnership. We are very pleased to further strengthen our team with his experience and look forward to his valued contribution to our clients and our firm.

We are launching our Book Review series on how to negotiate successfully. In episode No. 1 of our Book Review Series, Senior Partner Michael Bader reviews the book “Noise” written by psychologist and Nobel Prize winner Daniel Kahneman. The New York Times Bestseller was met with great response from business decision-makers and negotiators worldwide. "A smorgasbord of unexpected insights. [...] " (The Neue Zürcher Zeitung). Click here for the Video.